Moderately to severely decreased GFR and severely increased albuminuria. According to the 2012 KDIGO guidelines, an eGFR of 30–34 is moderately to severely decreased and an albuminuria level of >300 mg/g is severely increased7
It is important for Thomas to avoid nephrotoxins, urinary outflow obstructions and smoking-related cardiovascular disease
SGLT2i. Treatment with an SGLT2 inhibitor is recommended in most patients with an eGFR of ≥30 mL/min/1.73 m2, diabetes, and CKD5
Canagliflozin and dapagliflozin were assessed in the CREDENCE and DAPA-CKD trials, respectively13,14
Dapagliflozin became the first SGLT2i to receive approval by the EMA and FDA for the treatment of adults with chronic kidney disease with or without diabetes15,16